Načítá se...
Systemic immunosuppression in times of COVID‐19: Do we need to rethink our standards?
The current SARS‐CoV‐2 pandemic particularly endangers older people with pre‐existing cardiopulmonary and metabolic conditions. However, it is also currently under discussion whether patients under immunosuppressive therapy also have a higher risk of suffering a severe course of the COVID‐19 disease...
Uloženo v:
| Vydáno v: | J Dtsch Dermatol Ges |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7436367/ https://ncbi.nlm.nih.gov/pubmed/32743938 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ddg.14194 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|